These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38837100)

  • 1. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.
    Vogler S; Habimana K; Haasis MA; Fischer S
    Appl Health Econ Health Policy; 2024 Sep; 22(5):629-652. PubMed ID: 38837100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries.
    Vogler S; Windisch F
    Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 35892377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices.
    Steigenberger C; Windisch F; Vogler S
    Diagnostics (Basel); 2023 Dec; 13(23):. PubMed ID: 38066837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System.
    Anggriani Y; Ramadaniati HU; Sarnianto P; Pontoan J; Suryawati S
    Value Health Reg Issues; 2020 May; 21():1-8. PubMed ID: 31634791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model.
    Schurer M; Patel R; van Keep M; Horgan J; Matthijsse S; Madin-Warburton M
    Front Med Technol; 2023; 5():1010247. PubMed ID: 36860906
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.